StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for AUTL yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-18 | $1.62 | $1.80 | +11.11% | 6.0M |
| 05-19 | $1.81 | $1.63 | -9.94% | 1.7M |
| 05-20 | $1.64 | $1.62 | -1.22% | 0.9M |
| 05-21 | $1.61 | $1.65 | +2.48% | 0.7M |
| 05-22 | $1.67 | $1.70 | +1.80% | 1.0M |
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $26.22M | $75.39M | $51.10M | $29.91M |
Operating Income | $-59.51M | $-270.54M | $-198.08M | $-126.46M |
Net Income | $-71.60M | $-287.53M | $-197.20M | $-118.08M |
EPS (Diluted) | $-0.27 | $-1.08 | $-0.74 | $-0.44 |
Total Assets | $527.07M | $589.07M | $661.95M | $720.98M |
Total Liabilities | $418.24M | $410.94M | $396.50M | $374.52M |
Cash & Equivalents | $130.93M | $104.13M | $86.12M | $123.83M |
Free Cash Flow OCF − CapEx | $-68.00M | $-302.61M | $-236.17M | $-163.87M |
Shares Outstanding | 266.14M | 266.14M | 266.14M | 266.13M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.